2 recruiting, 1 active not recruiting, 1 completed, 1 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Advanced Sarcomatoid Renal Cell Carcinoma: new trials by email Literature Review of Advanced Sarcomatoid Renal Cell Carcinoma trials Research Report on Advanced Sarcomatoid Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2021-11-01 | 2026-03-05 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate - Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2012-08-01 | 2022-06-07 |
Carcinoma, Renal Cell (5) · Clear-cell metastatic renal cell carcinoma (4)
Adenocarcinoma (5) · Carcinoma (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Kidney Neoplasms (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5)
Nivolumab (3) · Specimen Handling (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · Magnetic Resonance Spectroscopy (2) · Bevacizumab (1) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1) · Sorafenib (1) · Sunitinib (1) · cabozantinib (1) · pazopanib (1) · tivozanib (1) · trebananib (1)
City of Hope Medical Center (3) · National Cancer Institute (NCI) (1) · Osel, Inc. (1)
United States (5)
Sumanta K Pal (2) · Alex Chehrazi-Raffle, MD (1) · Charles B Nguyen (1) · Thomas J Semrad (1)
P30CA033572 (5), N01CM00038 (1)